Efficacy of Paclitaxel Combined with Epirubicin Neoadjuvant Chemotherapy in the Treatment of Triple-negative Breast Cancer
ZHANG Li
Abstract：Objective:To investigate the clinical efficacy of Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.Method:Our hospital from February 2012 to October 2013 were treated 50 cases of triple-negative breast cancer patients for the study, they were divided into the control group(n=25) and the treatment group(n=25),the control group was given the pure Epirubicin adjuvant chemotherapy,the treatment group was given Paclitaxel combined with Epirubicin neoadjuvant chemotherapy,the treatment effect and adverse reactions of two groups were compared.Result:The treatment group,complete remission in 8 cases(32%),partial remission in 12 case(48%),the recent total effective rate was 80%.The control group,complete remission in 4 cases(16%),partial remission in 10 case(40%),the recent total effective rate was 56%,the difference was statistically significant(P<0.05).Conclusion:Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer has a good efficacy,is worthy of further research applications.
Keywords：PaclitaxelEpirubicinNeoadjuvant chemotherapyTriple-negative breast cancer
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 4-5,6 )